Lexaria Enters a New Pharmaceutical Agreement for DehydraTECH

Third pharmaceutical company relationship entered Kelowna, British Columbia – November 4, 2026 – TheNewswire - Lexaria Bioscience Corp. (Nasdaq: LEXX) (the “ Company ” or “ Lexaria ”), a global innovator in drug delivery platforms, announces that it has entered into an Agreement with an unnamed pharmaceutical company (“ PharmCo ”) to investigate Lexaria’s DehydraTECH technology with one or more proprietary PharmCo molecules. Today’s announcement is separate from, and has no relationship with, Lexaria’s two Material Transfer Agreements already existing with other pharmaceutical companies . The new Agreement outlines the conditions under which PharmCo will supply Lexaria with one or more proprietary molecule(s) which will then be processed with Lexaria’s patented DehydraTECH technology for evaluation. Lexaria expects that, if the evaluation process is successful, the parties will potentially move towards a licensing agreement with traditional terms including economics. At Pharmco’s request, Lexaria will not be disclosing Pharmco’s identity nor specific details of the new Agreement. Lexaria was introduced to PharmCo through Liberi Group, a global life sciences business development con

Plan Gratis · Plus 29 CA$ o Pro 99 CA$/mes